- 영문명
- Real World Prescription of Nonsteroidal Anti-inflammatory Drugs Contraindicated in Patients with Chronic Kidney Disease
- 발행기관
- 대한약학회
- 저자명
- 박채운(Chaeun Park) 천부순(Pusoon Chun)
- 간행물 정보
- 『약학회지』제69권 제4호(2025년), 395~402쪽, 전체 8쪽
- 주제분류
- 의약학 > 기타의약학
- 파일형태
- 발행일자
- 2025.08.31
4,000원
구매일시로부터 72시간 이내에 다운로드 가능합니다.
이 학술논문 정보는 (주)교보문고와 각 발행기관 사이에 저작물 이용 계약이 체결된 것으로, 교보문고를 통해 제공되고 있습니다.
국문 초록
A retrospective cross-sectional study was conducted to investigate prescription of nonsteroidal anti-inflammatory drugs (NSAIDs) contraindicated in patients with chronic kidney disease (CKD) using the Health Insurance Review and Assessment Service (HIRA) claims data 2023. Contraindicated NSAID prescriptions were identified using the generic name codes provided by HIRA, and contraindications were determined based on the primary and secondary diagnosis codes recorded immediately prior to the NSAID prescription. In 2023, 78,812 of 435,712 CKD patients (18.1%) received a total of 329,507 prescriptions of contraindicated NSAIDs. Among the 356,646 contraindicated NSAID prescription instances identified from the 329,507 prescriptions, 88.8% were non-selective NSAIDs (tNSAIDs) and 11.2% were coxibs. The majority of the contraindicated NSAIDs were prescribed in primary healthcare facilities (66.2%), followed by secondary (29.6%) and tertiary (4.2%) healthcare settings. Most of tNSAIDs (79.1%) and coxibs (76.9%) were prescribed to patients with estimated CKD stage 5, and the difference between two groups was negligible (absolute standardized difference [aSD] 0.053). Most tNSAIDs (88.1%) and coxibs (86.1%) were prescribed to outpatients (aSD 0.061). Among outpatient oral NSAIDs, 85.3% of tNSAID were prescribed for 7 days, while 23.1 and 10.7% of coxibs were prescribed for 16-30 days and for >30 days, respectively. Among the prescriptions for contraindicated NSAIDs, only 66.4% of tNSAID prescriptions and 62.3% of coxib prescriptions included indications for NSAID use in the primary or secondary disease code fields. Before prescribing NSAIDs to patients with CKD, it is important to carefully weigh the benefits of NSAID use against the potential risk of nephrotoxicity.
영문 초록
목차
서 론(Introduction)
방 법(Methods)
결 과(Results)
고 찰(Discussion)
결 론(Conclusion)
감사의말씀(Acknowledgment)
Conflict of Interest
References
키워드
해당간행물 수록 논문
- 약학회지 제69권 제4호(2025년) 목차
- 선택적인 PAK 저해제를 개발하기 위한 전략
- 환자 중심 의료제품 개발의 국제 동향 비교고찰 연구 - 미국과 유럽을 중심으로
- 당뇨병 치료제의 우선판매품목허가 현황 분석 및 전략 수립
- Innovative Technological Emerging Platform: Exploring PROTAC Research and Regulatory Trends
- 바이오의약품 생산용 세포배양배지의 오염관리 방안 연구
- 일본 식민기의 근대 약학교육과 여성
- Comparative Analysis of Real-World Data Utilization in Regulatory Decision-Making: Current Status in South Korea compared to FDA and EMA
- 온라인 검색 트렌드 분석과 텍스트마이닝을 활용한 식욕억제제 데이터 분석
- 습식 과립법을 이용한 정제 제작 시 부형제 조합 및 혼합비율이 품질 특성에 미치는 영향
- 만성 신장병 환자에서 금기 비스테로이드성항염증제의 처방 현황
참고문헌
교보eBook 첫 방문을 환영 합니다!
신규가입 혜택 지급이 완료 되었습니다.
바로 사용 가능한 교보e캐시 1,000원 (유효기간 7일)
지금 바로 교보eBook의 다양한 콘텐츠를 이용해 보세요!
